Table 1.
Inhibitory activity of EK1 peptide and EK1‐based lipopeptides against SARS‐CoV‐2 and its variants
| EK1 (IC50: nM) | EK1C4 (IC50: nM) | EKL1C (IC50: nM) | EK1‐C16 (IC50: nM) | |
|---|---|---|---|---|
| SARS‐CoV‐2 (PsV/Caco2) | 1270 | 5.8 | 49.0 | 480 |
| Alpha variant (PsV/Caco2) | 1240 | 5.5 | 12.0 | 190 |
| Gamma variant (PsV/Caco2) | 1250 | 6.6 | 46.0 | 260 |
| Delta variant (PsV/Caco2) | 430 | 9.8 | 32.0 | 110 |
| Omicron variant (live virus/Vero‐TMPRSS‐2) | 1138 | 85.0 | 182.2 | 750 |
| Omicron variant (PsV/Caco2) | 309 | 8.6 | 26.1 | 230 |
Note: Data are from our previously published papers.
Abbreviation: IC50, half maximal inhibitory concentration; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2.